The EUs 7th Framework programme

1
The EUs 7th Framework programme
Stéphane Hogan Head of Unit Applied Genomics
Biotechnology Health Directorate, DG Research,
European Commission
EU-Korea Biotech seminar
Seoul, 1 December 2005
2

• Presentation in 3 parts
• The current programme FP6 (2003-2006)
• The next programme FP7 (2007-2013)
• Cooperation

3

FP6 The Sixth Framework programme (2003-2006)
4
Why do research at European level?

• Motivations
• Pooling and leveraging resources
• Fostering human capacity and excellence in ST
• Better integration of European RD

5
Life sciences, genomics and biotechnology for
health
FP6
2.4 billion in 6th Framework programme (2003-06)

• Advanced genomics and its applications for health

1.1 Fundamental knowledge and basic tools for
functional genomics in all organisms 1.2
Applications of knowledge and technologies in the
field of genomics and biotechnology for health
Major diseases
2.1 Application oriented genomic approaches to
medical knowledge and technologies 2.2 Combating
cancer 2.3 Confronting the major communicable
diseases linked to poverty
6
Fundamental genomics
2005 budget 73m ( 35m for SME call)
FP6
Main areas for research

• Gene expression and proteomics
• Structural genomics
• Comparative genomics and population genetics
• Bioinformatics
• Multidisciplinary functional genomics approaches
  to basic biological processes

7
Genomics and biotechnology
2005 budget 87m ( 46m)
FP6
Main areas for research

• Rational and accelerated development of new,
  safer and more effective drugs
• Development of new diagnostics
• Development of in-vitro tests to replace animal
  experimentation
• Development and testing of new preventative and
  therapeutic tools, such as somatic gene and cell
  therapies (in particular stem cell therapies) and
  immunotherapies
• Research in post-genomics, with high potential
  for application

8
Major diseases
2005 budget 100m ( 45m)
FP6
Main areas for research

• Application-oriented genomics approaches
• Cardiovascular disease, diabetes and rare
  diseases
• Resistance to antibiotics and other drugs
• The brain and diseases of the nervous system
• Human development and ageing

9
Major diseases
2005 budget 49m ( 25m)
FP6
Main areas for research

• Combating cancer

10
Communicable diseases(HIV/AIDS, malaria
tuberculosis)
2005 budget 47m ( 20m)
Main areas for research

• Developing promising candidate vaccines and
  therapies
• Establishing a programme for advanced clinical
  trials through EDCTP www.edctp.org

11

FP7 The Seventh Framework programme
(2007-2013)
12
Whats new in FP7?

• Main elements of EC proposal compared to FP6
• Annual budget doubled (5 billion ? 10 billion)
• Collaborative research
• for Health 600m ? gt 1 billion
• Continuity in themes, instruments and duration
• Simplification of procedures
• Basic research the ERC (1.5 billion per year)
• Joint Technology Initiatives

13
FP7 proposed budget(EUR billion, 2004 constant
prices)
14
9 thematic priorities in FP7

• Health
• Food, agriculture and biotechnology
• Information and communication technologies
• Nanotechnologies, materials and new production
  technologies
• Energy
• Environment (including climate change)
• Transport (including aeronautics)
• Socio-economic sciences and the humanities
• Security and space
• Euratom Fusion energy research, nuclear
  fission and radiation protection

15

Health in FP7
16
Collaborative researchin Health

• Main policy drivers
• Improving the health of European citizens
• Increasing the competitiveness of European
  health-related industries and businesses
• Addressing global health issues, including
  emerging epidemics

17
Collaborative researchin Health

• Activities in 3 main areas
• Biotechnology, generic tools and technologies for
  human health
• Translating research for human health
• Optimising the delivery of healthcare to European
  citizens

18
Collaborative researchin Health

• 1 Biotechnology, generic tools and technologies
  for human health
• High-throughput research
• Detection, diagnosis and monitoring.
• Innovative therapeutic approaches and
  interventions
• Predicting suitability, safety and efficacy of
  therapies (incl. alternatives to animal
  testing)

19
Collaborative research in Health

• 2 Translating research for human health
• Integrating biological data and processes
  (large-scale data gathering, systems biology)
• Research on the brain and related diseases, human
  development and ageing
• Translational research in infectious diseases to
  confront major threats to public health
  (antimicrobial drug resistance, HIV/AIDS,
  malaria, TB, emerging epidemics)
• Translational research in other major diseases
  (cancer, cardiovascular disease,
  diabetes/obesity rare diseases and other
  chronic diseases)

20
Collaborative research in Health
3 Optimising the delivery of health care to
European citizens

• Enhanced health promotion and disease prevention
  (providing evidence of best public health
  measures life styles, interventions, special
  focus on mental health, etc.)
• Translating clinical research into clinical
  practice (patient safety, better use of
  medicines, benchmarking, pharmacovigilance, etc.)
• Quality, solidarity and sustainability of health
  systems (organisational and financial aspects,
  health systems, etc.)

21
Collaborative research in Health

• Two other strategic issues will be addressed
  across activities
• Child health
• The health of the ageing population

22
FP7 Health research
SUMMARY

• Continuity in collaborative research to
• develop new tools and technologies
• promote translational research
• enhanced efforts to optimise delivery of health
  care
• using usual FP funding and coordination
  mechanisms
• A novel approach to improve drug development
• The Innovative Medicines Initiative
• using the proposed Joint Technology Initiative
  in FP7

23
Innovative Medicines Initiative

• Aim
• To remove major bottlenecks in drug
  development,acting where research is the key.
• Long term objective
• To increase competitiveness of European
  pharmaceutical industry and foster Europe as the
  most attractive place for pharmaceutical RD,
  thereby enhancing access to innovative medicines
  for patients.

24
RD bottlenecksidentified by stakeholders
Source EFPIA, 2005
25
Innovative Medicines Initiative

• Addressing RD bottlenecks in 4 main areas
• Improved prediction for early indications of
  safety
• Improved clinical performance for early
  indications of efficacy using biomarkers
• Better knowledge management through collaboration
• Education and training leverage strengths,
  bridge gaps (pre-clinical - clinical research),
  promote interdisciplinarity.

26
Innovative Medicines Initiative

• INNOMED - pilot project in FP6
• An Integrated Project evaluated in April 2005
• 44 partners, including 23 from industry
• EU-contribution 12 million over 3.5 years
  (2006-2009)
• Comprises two scientific projects (efficacy and
  safety)
• ADDNEUROMED discovery of new biomarkers for
  Alzheimers disease
• PREDTOX correlation of omics technology results
  with conventional toxicology data (liver
  kidney)

27

Food, Agriculture Biotechnology in FP7
28
Collaborative research in Food, Agriculture
Biotechnology

• OBJECTIVES
• Build a European Knowledge-Based Bio-Economy
  (KBBE)
• Respond to social and economic challenges
• sustainable food production
• food-related disorders
• infectious animal diseases
• agriculture/fishery production and climate change
• high quality food, animal welfare and the rural
  context
• Support CAP and CFP
• Involve all stakeholders (incl. industry) in
  research
• Respond quickly to emerging research needs

29
Collaborative research in Food, Agriculture
Biotechnology

• RATIONALE
• Biotechnology and food companies / SMEs need to
  be competitive on the world market (European
  Strategy on Life Sciences and Biotechnology)
• Society demands safer and healthier food
• Renewable resources and biomass for non-food
  applications helps reducing dependence on
  hydrocarbon-based economy
• Society demands sustainable and eco-efficient
  production methods in agriculture/fishery/forestry
  
• International cooperation ensures optimal
  exploitation of resources and application of
  results

30
Collaborative research in Food, Agriculture
Biotechnology

• Activities in 3 main areas
• Sustainable production and management of
  biological resources from land, forest, and
  aquatic environments
• Fork to farm food, health and well being
• Life sciences and biotechnology for sustainable
  non-food products and processes

31
Collaborative research in Food, Agriculture
Biotechnology

• 1 Sustainable production and management of
  biological resources from land, forest, and
  aquatic environment
• Enabling research (omics, converging
  technologies, biodiversity) for micro-organisms,
  plants and animals
• Improved crops and production systems, incl.
  organic farming
• Sustainable, competitive and multifunctional
  agriculture, forestry and rural development
• Animal welfare, breeding and production
• Infectious diseases in animals, including
  zoonoses
• Policy tools for agriculture and rural development

32
Collaborative research in Food, Agriculture
Biotechnology

• 2 Fork to farm food, health and well being
• Consumer, societal, industrial and health aspects
  of food and feed
• Nutrition, diet related diseases and disorders
• Innovative food and feed processing
• Improved quality and safety of food, beverage and
  feed
• Total food chain concept
• Traceability

33
Collaborative research in Food, Agriculture
Biotechnology

• 3 Life sciences and biotechnology for
  sustainable non-food products and processes
• Improved crops, feed-stocks, marine products and
  biomass for energy, environment, and high added
  value industrial products novel farming systems
• Bio-catalysis new bio-refinery concepts
• Forestry and forest based products and processes
• Environmental remediation and cleaner processing

34

Nanosciences, Nanotechnologies, Materials and
new Production Technologies in FP7
35
Collaborative research in Nanosciences,
Nanotechnologies, Materials and new Production
Technologies

• Activities in 4 main areas
• Nanosciences and Nanotechnologies
• Materials
• New Production
• Integration of technologies for industrial
  applications

36
Collaborative research in Nanosciences,
Nanotechnologies, Materials and new Production
Technologies

• 1 Nanosciences Nanotechnologies
• Objective
• Increase and support the take up of knowledge
  generated in this revolutionary field for all
  industrial sectors
• Topics include
• interface and size dependent phenomena
• materials properties at nano-scale
• self assembly
• Metrology
• new concepts and approaches
• impacts on health and safety
• convergence of emerging technologies

37
Collaborative research in Nanosciences,
Nanotechnologies, Materials and new Production
Technologies

• 2 Materials
• Objective
• generate new knowledge to enable new industrial
  products and processes to be achieved, exploiting
  the potential of interdisciplinary approaches in
  materials research.
• Topics include
• high performance, sustainable and
  knowledge-based materials
• design and simulation
• nano-, bio- and hybrid materials and their
  processing
• chemical technologies
• materials processing industries

38
Collaboration in research

• Competitive advantage for Europe
• Mutual benefit and interest
• Critical and specific need

39
Collaboration in research

• FP6 and FP7 open to international collaboration
• Collaborative projects
• Individual researchers (Marie Curie fellowships)
• Participation of European researchers in Korean
  programmes
• Facilitation mechanisms

40
Collaboration in research

• Top 6 countries collaborating in Health research
• (for first 3 years of current programme)

Based on the number of participation in funded
proposal
41
Collaboration in research

• The ALLOSTEM Integrated Project
• The Development of immunotherapeutic strategies
  to treat haematological and neoplastic diseases
  on the basis of optimised allogeneic stem cell
  transplantation
• Coordinator Prof. Alejandro Madrigal, Anthony
  Nolan Research Institute, London, UK
• EU contribution 8 million over 3.5 years
• partners 29 from 13 countries
• Brazilian participant Prof. Ricardo Pasquini,
  Hospital de Clinicas, Universidade Federal do
  Parana, Curitiba (Bone marrow transplanation,
  immunogenetics)
• Argentine participant Dr. Javier Bordone, ITMO
  Fundacion Mainetti, Buenos Aires (Stem cell
  transplantation, immunogenetics)
• www.allostem.org

42
Human Resources and Mobility Coherence and
Complementarities
Contents ?
43
Marie Curie programmeInternational dimension

• Objectives
• Reinforce the international (extra-European)
  dimension of the European Research Area as a
  fundamental component of the EUs human resources
  in RD.

44
Marie Curie programme International dimension

• Main features
• Career development/life-long training for EU
  researchers
• Outgoing fellowships, with mandatory return
• Return and reintegration for European researchers
  abroad
• International co-operation through researchers
  from 3rd countries
• All Marie Curie host driven actions open to 3rd
  country nationals
• Incoming fellowships for knowledge enhancement
  and collaboration enrichment (optional return for
  researchers from certain areas)
• International cooperation scheme with EU
  neighbouring countries and ST agreement
  countries
• Support to scientific diasporas of Europeans
  abroad and foreigners within Europe

45
Collaboration in research

• Facilitating international collaborationbetween
  Korea and the European Union
• raising awareness of Koreans AND of Europeans
• for FP7 and for Korean programmes
• Information (web, networks, publications)
• Conferences, meetings and workshops
• BIO 2006,
• specific events

46

• Thank you
• Further information
• Stéphane Hogan, Head of unit, Biotechnology and
  Applied Genomics,
• DG Research, EC. Email stephane.hogan_at_cec.eu.int
  
• Web sites
• Life Sciences www.cordis.lu/lifescihealth
• INCO portal http//cordis.europa.eu.int/inco/home
  _en.html

47
Collaboration in research

• Third country participation in Health research
• (for first 3 years of current programme)

Estimated EC contribution to INCO target
countries